Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) CEO John Evans sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Beam Therapeutics Stock Performance Shares of BEAM stock opened at $23.47 on Monday. The stock has a 50-day simple moving average of $26.30 and a 200 day simple moving average of $28.62. The stock has a market capitalization of $2.42 billion, a P/E ratio of -27.29 and a beta of 2.20. Beam Therapeutics Inc. has a fifty-two week low of $20.23 and a fifty-two week high of $38.26. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.09.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. During the same period in the prior year, the company posted ($1.00) EPS. Beam Therapeutics’s quarterly revenue was down 94.2% on a year-over-year basis. On average, sell-side analysts expect that Beam Therapeutics Inc. will post -4.49 earnings per share for the current fiscal year.
Institutional Trading of Beam Therapeutics Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Beam Therapeutics in the second quarter worth $308,796,000. ARCH Venture Management LLC acquired a new position in Beam Therapeutics in the 2nd quarter valued at $155,771,929. ADAR1 Capital Management LLC bought a new position in Beam Therapeutics in the 1st quarter worth $34,467,000. MWG Caph Ltd bought a new position in Beam Therapeutics in the 4th quarter worth $35,119,000. Finally, Bank of America Corp DE acquired a new position in Beam Therapeutics during the 2nd quarter worth $24,733,000. 99.68% of the stock is owned by institutional investors. Analysts Set New Price Targets Several brokerages recently issued reports on BEAM. Wall Street Zen raised Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research report on Thursday. William Blair raised Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday. Finally, Wedbush reissued an “outperform” rating and issued a $65.00 price target on shares of Beam Therapeutics in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Beam Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.10.
Check Out Our Latest Stock Analysis on Beam Therapeutics
Beam Therapeutics Company Profile (Get Free Report)
Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments.
Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders.
See Also Five stocks we like better than Beam Therapeutics These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Cathie Wood přikoupila akcie společnosti Beam Therapeutics za 2,8 milionu USD; společnost má hotovost ve výši 1,15 miliardy USD, která by měla financovat její provoz do poloviny roku 2029.
Cathie Wood, the CEO and founder of Ark Investment Management, owns, through her various Ark ETFs, $220.4 million in Beam Therapeutics (BEAM -5.09%) shares. It is a healthcare company that focuses on gene editing to develop precision medicines.
She has owned shares in Beam through her various Ark Technology ETFs for more than five years. On Oct. 12 and Oct. 13, she spent an additional $2.8 million on Beam shares for her Ark Genomic Revolution (ARKG -5.16%) fund. .
The company is a long way from profitability, but thanks to its potential, it is a worthwhile biotech stock to buy if you're willing to handle some volatility and risk.
The stock is down more than 14% this year. Here are three reasons to buy the stock whenever it dips.
Image source: Getty Images.
Beam has a distinct gene-editing technique
Unlike first-generation CRISPR-Cas9 technologies, which cause double-stranded DNA breaks and carry risk for unintended chromosomal rearrangements, Beam specializes in base editing. This technology allows precise, single-letter chemical edits to the genome without cutting both DNA strands.
$23.47-$1.26 (-5.09%)
NASDAQ · As of 4:00 PM ET 10/16/26
The technology precisely changes a specific nucleotide, or letter, in the genetic code. This enables potentially safer, more precise, and highly repeatable therapies, placing Beam at the forefront of the next wave in genomic medicine.
The company recently filed a lawsuit against Serapha Bio and its Chinese partner, YolTech Therapeutics, alleging the companies, with the assistance of a former Beam employee, developed an experimental alpha-1 antitrypsin deficiency (AATD) treatment using stolen trade secrets from Beam.
It has a deep clinical pipeline
Beam's therapies are still in early trials, but it has eight in its pipeline, giving it better odds of developing a blockbuster product. The pipeline focuses on high-value disease areas such as sickle cell disease (SCD), AATD, and other blood disorders.
The company's lead therapy is ristoglogene autogetemcel (risto-cel), which is in early trials. It is an investigational autologous therapy for the treatment of severe SCD. And it's an ex vivo cell therapy using base editing to genetically modify a patient's own hematopoietic stem cells to produce fetal hemoglobin and suppress sickling.
A large cash runway and tier-1 strategic partnerships
Biotech stocks on a pullback often carry solvency risk, but Beam maintains a relatively strong balance sheet. Backed by major pharmaceutical collaborations, including partnerships with Pfizer and Eli Lilly, and a solid cash buffer, Beam has a clear runway to fund its core clinical trials through key milestones without immediate pressure to pursue dilutive emergency capital raises.
As of the second quarter, the company reported having $1.15 billion in cash, enough, it said, to support operations through mid-2029.
Risk, but with ample reward potential
Beam reported only $32.2 million in revenue through its first six months, though that was up 50.5% year over year. It reported a $2.09 loss per share, an improvement from a $2.12 loss in the same period a year ago.
As its programs advance through phase 1/2 clinical trials, the next 12 to 18 months carry dense regulatory and clinical data readouts. If the company can show positive data on the trial readouts, that would likely significantly boost the stock.
Pomerantz LLP prověřuje možné porušení federálních zákonů o cenných papírech společností Beam Therapeutics po zveřejnění klinických dat studie BEAM-302; akcie 8. září klesly o 9,54 % na 26,83 USD.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Beam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 8, 2026, Beam issued a press release “announc[ing] updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD).” Although the Company said that “treatment with single-dose BEAM-302 was well tolerated with an acceptable safety profile in both Part A and Part B cohorts”, the press release also disclosed that “[t]ransient and predominantly Grade 1 alanine transaminase (ALT) and/or aspartate aminotransferase (AST) elevations were also observed.”
On this news, Beam’s stock price fell $2.83 per share, or 9.54%, to close at $26.83 per share on September 8, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Společnost Beam Therapeutics uvedla, že BEAM-301 po jediné dávce u dvou hodnotitelných pacientů s GSDIa v kohortě s dávkou 40 mg prodloužil dobu kontrolovaného lačnění na nejméně 15 hodin.
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa
Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints
Safety Profile of BEAM-301 Consistent with LNP-based Therapies
Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), taking place October 27-30, 2026, in Hamburg, Germany. BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, one of the most prevalent disease-causing mutations in GSDIa and one that is associated with the most severe form of the disease.
“People living with GSDIa face a relentless daily burden, including dependence on frequent starch administration, even throughout the night, to maintain glucose levels and prevent life-threatening hypoglycemia,” said Amy Simon, M.D., chief medical officer of Beam. “These initial data provide the first clinical evidence suggesting that BEAM-301, a base editing therapy designed to directly correct an underlying disease-causing mutation in patients with GSDIa, restored endogenous glucose production following a single in vivo treatment. Most notably, evaluable patients in the 40 mg cohort achieved ≥15 hours of controlled fasting and experienced substantial reductions in starch requirements. While follow-up remains ongoing, these findings support the transformative potential of BEAM-301 and represent an important proof of concept that precision genetic medicines, customized to a patient’s specific mutation, can address the root cause of their disease.”
Details are as follows:
Title: Initial Data from the Phase 1/2 Clinical Study of BEAM-301, an In Vivo Base Editor Targeting the R83C Variant in Glycogen Storage Disease Type Ia (GSDIa)
Poster ID: P0219
Presentation Session: Poster Session I
Presentation Session Time: Wednesday, October 28, 1:30–3:30 p.m. CET
Presenter: Rebecca Riba-Wolman, M.D., Connecticut Children's Hospital
Key Highlights:
As of the June 26, 2026, data cutoff, six patients received a single intravenous infusion of BEAM-301, including three patients treated with 20 mg and three patients treated with 40 mg. Median follow-up was 313 days (range, 249–453) in the 20 mg cohort and 53 days (range, 5–110) in the 40 mg cohort. One patient in the 40 mg cohort was not evaluable for efficacy as of the data cutoff.BEAM-301 demonstrated an acceptable safety profile that was consistent with LNP-based therapies. All patients experienced at least one treatment-emergent adverse event considered related to BEAM-301. Five serious adverse events were reported and resolved within two to 10 days, including three Grade 3 infusion-related reactions (IRRs). The use of shorter-acting steroids as premedication, which is typical in this patient population, may have contributed to the Grade 3 IRRs observed. The steroid premedication regimen has since been optimized. All transaminase elevations were transient and resolved without intervention. With the exception of a single Grade 2 elevation in aspartate aminotransferase (AST), all transaminase elevations were Grade 1. No dose-limiting toxicities, treatment discontinuations due to treatment-emergent adverse events, or deaths were reported.Dose-dependent improvements in time to fasting hypoglycemia (TTH) were observed. At baseline, median TTH was 2.9 hours in the 20 mg cohort and 2.5 hours in the 40 mg cohort. By Day 36, median TTH increased to 4.3 hours in the 20 mg cohort, while both evaluable patients in the 40 mg cohort achieved the protocol-defined maximum controlled fasting duration of ≥15 hours, consistent with restored endogenous glucose production.Reductions in prescribed daily starch intake were observed following treatment with BEAM-301. Decreases from baseline in prescribed daily starch intake guided by continuous glucose monitoring were 74% (Day 128), 71% (Day 227), and 11% (Day 387) in the 20 mg cohort, and 71% (Day 50) and 92% (Day 93) in the 40 mg cohort. Corresponding daily starch doses decreased by 0–4 and 2–4 doses/day in the 20 mg cohort and the 40 mg cohort (baseline: 6–7 and 5–6 doses/day), respectively. Triglyceride levels were comparable to baseline at last follow-up.Updated data from the ongoing Phase 1/2 trial will be presented during the ESGCT poster session. ESGCT Investor Event Information
Beam will host a live and webcast investor event on Tuesday, October 27, at 8:00 a.m. ET to review the data presented at this year’s ESGCT congress. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the company's website at www.beamtx.com. The archived webcast will be available on the company’s website beginning approximately two hours after the event.
About BEAM-301
BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, one of the most prevalent disease-causing mutations and one that results in the most severe form of glycogen storage disease type Ia (GSDIa). BEAM-301 is being evaluated in a Phase 1/2, open-label, dose-exploration and dose-expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy in patients with GSDIa.
About Glycogen Storage Disease Type Ia (GSDIa)
GSDIa is an autosomal recessive disorder caused by mutations in the G6PC1 gene that disrupt a key enzyme, glucose-6-phosphatase (G6Pase), critical for maintaining glucose homeostasis. Inhibition of G6Pase activity results in low fasting blood glucose levels that can result in seizures and death. Patients with the G6PC1 R83C mutation typically require frequent cornstarch administration, without which they may enter into hypoglycemic shock within one to three hours. There remains significant unmet need for patients with GSDIa.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our base editing technology and BEAM-301; the potential of BEAM-301 to restore endogenous glucose production and reduce starch requirements in patients with GSDIa; the significance of the initial clinical data as proof of concept for precision genetic medicines; our expected presentation at the ESGCT conference; our plans to advance BEAM-301 and our other programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events that could delay, limit or prevent further clinical development; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Pomerantz LLP prověřuje společnost Beam Therapeutics kvůli možnému porušení zákonů o cenných papírech. Akcie BEAM po zveřejnění klinických dat 8. září 2026 klesly o 9,54 % na 26,83 USD.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Beam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 8, 2026, Beam issued a press release "announc[ing] updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD)." Although the Company said that "treatment with single-dose BEAM-302 was well tolerated with an acceptable safety profile in both Part A and Part B cohorts", the press release also disclosed that "[t]ransient and predominantly Grade 1 alanine transaminase (ALT) and/or aspartate aminotransferase (AST) elevations were also observed."
On this news, Beam's stock price fell $2.83 per share, or 9.54%, to close at $26.83 per share on September 8, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Beam Therapeutics čelí vyšetřování kvůli možnému porušení zákonů o cenných papírech po zveřejnění dat z klinické studie BEAM-302. Akcie v ten den klesly o více než 9,5 %.
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or “the Company”) (NASDAQ: BEAM) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Beam informed investors on September 8, 2026, that it had “updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD)." According to the Company, "treatment with single-dose BEAM-302 was well tolerated with an acceptable safety profile in both Part A and Part B cohorts," but also revealed that "transient and predominantly Grade 1 alanine transaminase (ALT) and/or aspartate aminotransferase (AST) elevations were also observed." Based on this news, shares of Beam fell by more than 9.5% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Beam Therapeutics oznámila, že po jednáních s FDA chce pro BEAM-302, terapii pro AATD, usilovat o zrychlené schválení. Data z 29 pacientů ukázala přijatelnou bezpečnost a silné biomarkerové výsledky.
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD).
AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease.
The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and lung complications associated with the disease.
Promising Efficacy and Safety ProfileThe clinical trial evaluated single doses of BEAM-302 across two groups: Part A for patients with AATD-related lung disease and Part B for those with mild to severe liver disease.
As of the June 2026 data cutoff, results from 29 patients demonstrated an acceptable safety profile. The most frequent side effects were mild-to-moderate infusion-related reactions, affecting 41% of participants.
Read Next
Researchers also observed mostly mild, temporary liver enzyme elevations.
Patients receiving a 60 mg dose achieved sustained, functional alpha-1 antitrypsin (AAT) levels well above the protective 11 µM threshold. The therapy also reduced human neutrophil elastase activity and cut mutant Z-AAT proteins by 84% in both cohorts.
Additionally, BEAM-302 decreased toxic protein aggregates known to worsen liver disease and amplify lung inflammation. After treatment, newly produced, corrected M-AAT made up 93% of circulating AAT, exceeding the levels typically seen in genetic carriers.
Path To Accelerated ApprovalFollowing discussions with the U.S. Food and Drug Administration (FDA), Beam plans to pursue an accelerated approval pathway for the therapy.
The submission will evaluate AAT biomarkers over a 12-month period using the 60 mg dose as the primary endpoint.
To support a future biologics license application, the biotechnology firm anticipates enrolling roughly 50 additional patients with AATD-associated lung disease into an expansion of the ongoing trial.
Beam initiated dosing for this pivotal global cohort in July.
BEAM Stock Price Activity: Beam Therapeutics shares were down 7.17% at $27.53 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Read Next
Market News and Data brought to you by Benzinga APIs
Beam Therapeutics jmenovala Erica Fostera ředitelem pro komerční záležitosti. Povede komerční strategii firmy při přípravě možného uvedení risto-cel v roce 2027.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.
“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are impressive, including spearheading the commercial success of multiple blockbuster rare disease franchises at Horizon Therapeutics during a period of significant growth prior to its acquisition by Amgen. As we prepare for the potential launch of risto-cel in 2027, Eric's experience building strong teams and culture, defining and executing clear commercial strategies, and leading through growth will be invaluable as we lay the foundation for Beam's next chapter and work to bring multiple precision genetic medicines to patients in the years ahead.”
Mr. Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx. Prior to Ardelyx, Mr. Foster served as senior vice president and U.S. general manager at Amgen following the acquisition of Horizon Therapeutics in October 2023. At Horizon, he was senior vice president and general manager of the gout and ophthalmology business units, where he led operations for franchises that represented $2.75 billion in net sales revenue. Prior to his time at Horizon, from 2010 to 2021, Mr. Foster held roles of increasing responsibility in sales and marketing at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as vice president of immunology marketing, senior global marketing director and field sales vice president. Mr. Foster began his career in sales and market access at Johnson & Johnson. Mr. Foster holds a Bachelor of Arts in Economics from the University of Georgia and a Master of Business Administration from Auburn University.
“I'm excited to join Beam at such an important moment in the company's evolution,” said Foster. “Beam has built one of the most innovative platforms and deepest pipelines in biotechnology, with the potential to redefine how serious genetic diseases are treated. I look forward to partnering with the talented team at Beam to build a leading commercial organization, establish the capabilities needed to support multiple potential launches and, ultimately, bring these transformative medicines to patients.”
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Foster; the contributions Mr. Foster may make in his role with the company; the therapeutic applications and potential of our technology; the anticipated timing of potential product launches, including any potential launch of risto-cel; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Beam Therapeutics Inc. (BEAM - Free Report) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -18.00%. A quarter ago, it was expected that this company would post a loss of $0.87 per share when it actually produced a loss of $0.91, delivering a surprise of -4.6%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Beam Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.49 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 98.38%. This compares to year-ago revenues of $8.47 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Beam Therapeutics shares have lost about 6.5% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Beam Therapeutics?While Beam Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Beam Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.05 on $30.33 million in revenues for the coming quarter and -$4.16 on $122.7 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, EyePoint (EYPT - Free Report) , is yet to report results for the quarter ended June 2026.
This drug delivery technology company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of -8.2%. The consensus EPS estimate for the quarter has been revised 8.9% lower over the last 30 days to the current level.
EyePoint's revenues are expected to be $0.25 million, down 95.3% from the year-ago quarter.
Beam Therapeutics oznámila podání první dávky pacientovi v globální pivotní kohortě probíhající studie BEAM-302 pro AATD. Firma zároveň uvedla, že má 1,2 miliardy USD v hotovosti a cenných papírech.
August 04, 2026 07:00 ET | Source: Beam Therapeutics
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026
Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)
Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer of Beam Therapeutics. “Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise. Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel. With the continued expansion and advancement of our base editing pipeline, we have the potential to deliver transformative therapies for many patients with serious genetic diseases.”
Second Quarter 2026 and Recent Progress and Anticipated Milestones
Liver-targeted Genetic Disease Franchise
BEAM-302: Beam’s lead genetic disease program is designed to be a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and therefore has the potential to address both liver and lung manifestations of AATD.
In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease. The cohort is designed to support a potential accelerated approval path in the United States.Detailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026, in Barcelona, Spain. BEAM-304: BEAM-304 is designed to leverage Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using an innovative platform approach with the goal of creating mutation-specific base editors for the majority of patients with PKU.
In June, Beam announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for BEAM-304.Beam has initiated clinical start-up activities for the planned Phase 1/2 trial for BEAM-304. The trial will initially evaluate safety, tolerability, and reduction of blood Phe levels in PKU patients with the R408W mutation, one of the most prevalent disease-causing mutations among patients with PKU in the U.S., with a goal of establishing clinical proof of concept for base editing in PKU. The trial will subsequently evaluate base editors for additional mutations within a single clinical program.In July, updated preclinical data for BEAM-304 were presented at the Federation of American Societies for Experimental Biology (FASEB) Genome Engineering: Research and Applications Conference. The presentation is available on the Presentation and Publications page of Beam’s website beamtx.com.
BEAM-301: BEAM-301 aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).
BEAM-301 is currently being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.Beam expects to report initial clinical data in 2026. Hematology Franchise
Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD).
Dosing is complete in all adult and adolescent patients enrolled in the Phase 1/2 BEACON trial.Beam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026. Next-generation Programs in Sickle Cell Disease and Hematology:
Beam completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody with the potential to enable non-genotoxic ex vivo and in vivo therapies for SCD. Treatment with BEAM-103 was well tolerated across all doses tested.Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in lead optimization. Second Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2026, compared to $1.2 billion as of December 31, 2025.Research & Development (R&D) Expenses: R&D expenses were $95.1 million for the second quarter of 2026, compared to $101.8 million for the second quarter of 2025.General & Administrative (G&A) Expenses: G&A expenses were $31.9 million for the second quarter of 2026, compared to $26.9 million for the second quarter of 2025.Net Income (Loss): Net loss was $122.7 million, or $1.18 per share, for the second quarter of 2026, compared to net loss of $102.1 million, or $1.00 per share, for the second quarter of 2025. Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304; our planned submission of a BLA for risto-cel; our expectations regarding the anticipated launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our expected presentations at upcoming medical conferences, including at the ERS Congress; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Condensed Consolidated Balance Sheet Data (unaudited)(in thousands) June 30,
2026 December 31,
2025Cash, cash equivalents, and marketable securities$1,152,927 $1,245,210 Total assets 1,386,355 1,481,177 Total liabilities 318,913 242,819 Total stockholders’ equity 1,067,442 1,238,358 Condensed Consolidated Statement of Operations (unaudited)(in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025License and collaboration revenue$490 $8,466 $32,228 $15,936 Operating expenses: Research and development 95,096 101,758 199,620 200,574 General and administrative 31,947 26,859 66,376 54,799 Total operating expenses 127,043 128,617 265,996 255,373 Loss from operations (126,553) (120,151) (233,768) (239,437)Other income (expense): Change in fair value of derivative liabilities (4,200) 1,300 (1,700) 4,500 Change in fair value of non-controlling equity investments 338 4,415 354 2,334 Change in fair value of contingent consideration liabilities (205) (28) 309 (55)Gain on sale of equity method investment 455 — 455 — Interest and other income (expense), net 7,487 12,326 17,354 22,190 Total other income (expense) 3,875 18,013 16,772 28,969 Net loss$(122,678) $(102,138) $(216,996) $(210,468)Unrealized gain (loss) on marketable securities (1,119) (150) (3,300) (669)Comprehensive loss$(123,797) $(102,288) $(220,296) $(211,137)Net loss per common share, basic and diluted$(1.18) $(1.00) $(2.09) $(2.21)Weighted-average common shares outstanding, basic and diluted 104,325,436 101,995,184 103,797,276 95,023,977
Cathie Wood dál nakupuje Beam Therapeutics, jejíž pozice má hodnotu přes 300 milionů USD. Firma má 1,21 miliardy USD v hotovosti a několik klinických katalyzátorů.
Cathie Wood of Ark Invest first bought shares of Beam Therapeutics (BEAM 4.36%), a biotech focused on precision genetic treatments, in 2020. She's continued to acquire shares since then, with her most recent purchases last week clocking in at around $4 million.
Today, Wood's position in Beam is worth more than $300 million. That's not trivial, even for Wood. Of course, the question is: When it comes to Beam, should you follow her lead? I maintain that if you're comfortable with the risks of an early-stage biotech company, you should.
Beam is taking a different approach to gene editing CRISPR gene editing involves cutting both strands of DNA before inserting or removing genetic material. Beam Therapeutics, however, uses a different technology called base editing.
Instead of cutting DNA, base editing changes a single DNA letter directly. Think of it as correcting a typo in a document rather than deleting an entire sentence and rewriting it. The approach is designed to make genetic edits more precise.
Image source: Getty Images.
That technology becomes quite attractive when you consider that among more than 50,000 documented disease-causing genetic variants, roughly 60% are point mutations (a genetic alteration in which a single nucleotide in a DNA or RNA sequence is changed), making them potential targets for base editing.
A maturing pipeline Beam now has several clinical programs that could create significant value over the next few years. Its most advanced liver-disease program, BEAM-302, is being developed for alpha-1 antitrypsin deficiency (an inherited disorder that leaves the liver and lungs vulnerable to progressive damage).
Updated phase 1/2 data showed that a single treatment produced substantial increases in functional alpha-1 antitrypsin protein. The company has selected its optimal dose and expects to begin a global clinical trial in the second half of 2026.
Beam is also developing ristoglogene autogetemcel (risto-cel), a potential one-time treatment for sickle cell disease. So far, clinical results have been encouraging, showing that the therapy can restore healthy function to red blood cells by increasing production of fetal hemoglobin. This is a key protein that helps prevent the painful complications caused by the disease.
The company expects to file for approval from the U.S. Food and Drug Administration (FDA) by the end of 2026. If approved, risto-cel would become Beam's first commercial product, transforming it from a company focused solely on research into one capable of generating product revenue.
Beam also plans to seek FDA approval to begin human testing of BEAM-304, a potential treatment for phenylketonuria (PKU). This rare inherited disorder prevents the body from properly breaking down the amino acid phenylalanine. Left untreated, the condition can lead to serious neurological problems.
The company will also soon report its first clinical results for BEAM-301, a treatment for glycogen storage disease type Ia, a rare genetic disorder that prevents the liver from properly regulating blood sugar. While both programs are still in the early stages, they broaden Beam's pipeline and provide additional opportunities to create long-term value if the therapies prove successful.
Plenty of cash One of the biggest risks for early-stage biotech companies is running out of cash before reaching meaningful clinical milestones. Beam appears to be in a stronger position than many of its peers.
At the end of the first quarter, the company reported $1.21 billion in cash, cash equivalents, and marketable securities. Management believes that its cash, combined with a financing deal it has with specialty finance firm Sixth Street, is sufficient to fund operations through mid-2029. That gives Beam time to advance multiple clinical programs without immediately returning to capital markets for additional financing.
Today's Change
(
-4.36
%) $
-1.20
Current Price
$
26.33
Of course, none of this guarantees success. Beam Therapeutics reported a net loss of $94.3 million in Q1. Every major value driver still depends on successful clinical trials, regulatory approvals, and eventual commercialization. Failure in even one late-stage program could significantly affect the stock.
Competition also continues to intensify. Companies including CRISPR Therapeutics and Verve Therapeutics (now a subsidiary of Eli Lilly) continue advancing their own gene-editing platforms. Beam's long-term success depends not only on proving that base editing works, but also that it offers meaningful advantages over competing technologies.
Wood typically invests in companies capable of creating entirely new markets rather than simply improving existing ones. Beam fits that profile. The company has a differentiated gene-editing platform, multiple late-stage clinical catalysts over the next 18 months, more than $1.2 billion on its balance sheet, and enough capital to execute its development strategy well into 2029.
That doesn't make Beam a low-risk investment. Clinical-stage biotechnology rarely is. But if you're willing to accept the volatility that comes with drug development, Beam Therapeutics appears to be one of the more compelling gene-editing companies on the market today.
